by Alison Bass | Nov 26, 2012 | biotech industry, drug marketing, medical devices, opiods, pharmaceutical industry, prescription drug abuse, public health, Uncategorized
In my previous blogs about West Virginia’s shockingly high rate of prescription drug overdoses — the Mountain State has the second highest rate of overdoses in the nation — I focused on “the culture of disability” that created this...
by Alison Bass | May 16, 2012 | clinical trials, conflicts of interest, drug marketing, FDA, medical devices, pharmaceutical industry, public health
Congress is moving quickly to pass a bill that would authorize higher industry fees for the FDA in exchange for speeding up the approval of some drugs and medical devices and eliminating restrictions on financial conflicts of interest among the agency’s advisory...
by Alison Bass | Apr 27, 2012 | antidepressants, biotech industry, clinical trials, continuing medical education, drug marketing, FDA, health care costs, medical devices, patient care, pharmaceutical industry, scientific misconduct, suicide rates, Uncategorized
Is the Food and Drug Administration violating its own mandate to approve safe drugs? That was the question that Donald Light, co-author of The Risk for Prescription Drugs and a long-time medical sociologist, posed at a talk yesterday at Brandeis University. The...
by Alison Bass | Oct 28, 2011 | antidepressants, conflicts of interest, FDA, medical devices, suicide rates
With the Obama administration hobbled by a Republican-led Congress, the pharmaceutical and medical device industry seems to have launched a concerted push to roll back regulatory initiatives designed to protect consumers from unproven or unsafe drugs and medical...
by Alison Bass | Aug 10, 2011 | drug marketing, ghostwriting, medical devices, scientific journal retractions, university industry collaboration
The retraction of studies in medical and scientific journals has surged in the last decade, according to separate analyses done by the Wall Street Journal and Retraction Watch. In its page-one article today, the Journal noted that while just 22 retraction notices...
by Alison Bass | Jun 27, 2011 | biotech industry, conflicts of interest, drug marketing, health care costs, medical devices, pharmaceutical industry
A page-one story in The Boston Globe today spotlights the Massachusetts biotech industry’s effort to block a key piece of President Obama’s health care overhaul: the creation of an independent payment advisory board (IPAB) that would make recommendations...